Telemedicine is a sector of immense growth potential with a market size of about $730 Mn in 2022 with a CAGR of about 19.7% and is expected to grow to $3,075 Mn in 2030 as predicted by Insights10 report on the Australia Telemedicine Market Analysis. The inclusion of telemedicine services by general practitioners and telemedicine coverage in Medicare Australia are major growth drivers. The market is segmented by component, modality, application, and end user. Doxy.me Inc. and Teladoc Health are major market players in telemedicine.
By 2030, it is anticipated that the Australia dermatology drugs market will reach a value of $516 Mn from $204 Mn in 2022, growing at a CAGR of 12.3% during 2022-2030. The market is primarily dominated by local players such as Faulding, Bioscience International, Aspen Pharmacare, and Alpha pharm. The market is driven by an aging population, disparities in universal health coverage, and the launch of new and innovative drugs. This market is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.
Australia's Electronic Health Record market size was valued at $339 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.5% from 2022-30 and will reach $521 Mn in 2030. Australia's EHR market growth will grow as EHRs give doctors access to more thorough patient data, empowering them to swiftly decide on the best course of treatment, enhance patient care, and reduce safety risks. The key market players are Medical Director, Zedmed, Genie Solutions, Allscripts, Cerner, Epic Systems, and others.
This report presents a strategic analysis of the Australia Sleep Disorders Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Sleep Disorders Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the Australia Antibacterial (Antibiotics) Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Australian antibacterial (Antibiotics) Drugs Market, offering unmatched value, accuracy, and expert insights.
The growing prevalence of Alzheimer's disease in elderly women in Australia is responsible for the growth of Australia Alzheimer's disease market. The market is segmented by product, drug, and distribution channel. Roche, Eisai, and Novartis are some of the key competitors in the market.
Australia's Oral Care market was valued at $423 Mn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $765 Mn in 2030. One of the main reasons propelling the growth of this market is Increasing Disposable Income and the ageing population. The market is segmented by type, drug, and distribution channel. Some key players in this market are White Glo, Grants of Australia, Red Seal, Dr. Brite, and Pure Smile among others.
Australia's acne therapeutics market is expected to grow from $120 Mn in 2022 to $226 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-2030. More than 90% of Australian teenagers suffer from acne vulgaris which leads to the increasing demand for acne treatment options in Australia thereby driving the growth of Australia's acne therapeutics market. The market is segmented by treatment, route of administration, age group, and by distribution channel. Some of the major players in the Australian acne therapeutics market are Sypharma, BioDiem, and Novan.
Australia home healthcare market is projected to grow from $4.35 Bn in 2022 to $8.94 Bn in 2030 with a CAGR of 9.43% for the year 2022-2030. The market has witnessed significant growth post-pandemic. The market is segmented by product, service, software, and by region.
Lung cancer is the fifth most common type of cancer affecting the Australian population, therefore the Australia lung cancer drugs market is projected to grow during the forecast period. The market is segmented by type, treatment, end user, route of administration, and distribution channel.
Australia Over The Counter (OTC) drugs market is projected to grow from $2.04 Bn in 2022 to $3.95 Bn in 2030 with a CAGR of 8.6% for the year 2022-2030. Major OTC innovation trends include treatment based, lifestyle based, format based and extended offering. The market is segmented by drug type and by distribution channel.
Australia Primary Hyperoxaluria (PH) market stood at around $2.1 Mn in 2022 and is projected to reach $8.8 Mn with a CAGR of 19% for the year 2022-2030. The market is segmented by type, diagnosis, drug, treatment and by distribution channel. Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are some of the key players in the Australia PH market.